Skip to main content

Table 4 Analyses of risk factors for poor clinical outcomes in the TB-HBV group (n = 58)

From: Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment

Factors

Univariate analysis

Multivariate analysis

OR

95%CI

P-value

OR

95%CI

P-value

Age > 50

3.791

1.23, 11.69

0.020

3.317

0.91, 12.04

0.068

Male

2.625

0.27, 25.14

0.402

–

–

–

Alcohol intake > 40 g/d

5.069

0.58, 44.36

0.143

2.744

0.19, 40.15

0.461

INH + RFP

1.173

0.36, 3.80

0.790

–

–

–

Latency < 1 month

0.979

0.21, 4.57

0.978

–

–

–

Hepatocellular DILI

1.507

0.47, 4.80

0.488

–

–

–

Cirrhosis

4.76

1.44, 15.76

0.011

6.320

1.53, 26.06

0.011

HBV DNA > 20,000 IU/ml

3.800

1.16, 12.52

0.028

5.808

1.37, 24.64

0.017

NA treatment

1.071

0.36, 3.33

0.905

–

–

–

  1. Only variables with P < 0.200 in the univariate analysis were included in the multivariate analysis
  2. Abbreviations: INH isoniazid, RFP rifampin, DILI drug-induced liver injury, HBV hepatitis B virus, NA nucleos(t)ide analogue
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us